Skip to main content

Table 1 Baseline patients characteristics

From: Angiopoietin 1 release from human neutrophils is independent from neutrophil extracellular traps (NETs)

 

HC (n = 34)

T2DM group (n = 8)

Stable HFpEF (n = 5)

Stable HFpEF + T2DM (n = 7)

ADHFpEF (n = 7)

ADHFpEF + T2DM (n = 6)

Age (years)

 

68 ± 1.7

75 ± 3.3

71 ± 3.2

82 ± 3.0*

73 ± 3.5

Males n (%)

20 (58.8%)

6 (75%)

2 (40%)

4 (57.1%)

2 (28.6%)

4 (66.7%)

NYHA classification n (%)

Class I

n/a

n/a

0 (0%)

1 (14.3%)

0 (0%)

0 (0%)

Class II

n/a

n/a

3 (60%)

5 (71.4%)

2 (28.6%)

1 (16.7%)

Class III

n/a

n/a

2 (40%)

1 (14.3%)

2 (28.6%)

2 (33.3%)

Class IV

n/a

n/a

0 (0%)

0 (0%)

2 (28.6%)

2 (33.3%)

Etiology n (%)

Ischemia

n/a

n/a

0 (0%)

1 (14.3%)

0 (0%)

2 (33.3%)

Cardiomyopathy

n/a

n/a

1 (20%)

5 (71.4%)

3 (42.9%)

1 (16.7%)

Valvular

n/a

n/a

0 (0%)

3 (42.9%)

1 (14.3%)

2 (33.3%)

Others

n/a

n/a

4 (80%)

0 (0%)

4 (57.1%)

0 (%)

LVEF (%)

n/a

n/a

54 ± 2.1

58 ± 1.5

57 ± 2.6

55 ± 1.3

Hypertension

n/a

6 (75%)

5 (100%)

7 (100%)

4 (57.1%)

6 (100%)

Dyslipidemia

n/a

7 (87.5%)

1 (20%)

4 (57.1%)

3 (42.9%)

5 (83.3%)

Stroke

n/a

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

Biochemistry

Creatinine (μmol/l)

n/a

86.7 ± 8.6

147 ± 43

146 ± 17

127 ± 21

166 ± 26

Glucose (mmol/l)

n/a

9.0 ± 0.7

5.7 ± 0.6*

6.9 ± 0.6

6.4 ± 0.6

8.0 ± 0.6

Triglyceride (mmol/l)

n/a

1.35 ± 0.19

1.02 ± 0.12

2.06 ± 0.56

 

1.43 ± 0.13

LDL (mmol/l)

n/a

1.80 ± 0.12

2.23 ± 0.80

1.09 ± 0.23

 

1.64 ± 0.50

Medication n (%)

ACEi

n/a

3 (37.5%)

0 (0.0%)

1 (14.3%)

0 (0.0%)

1 (16.7%)

ARBs

n/a

5 (62.5%)

0 (0.0%)

2 (28.6%)

1 (14.3%)

0 (0.0%)

β-blockers

n/a

3 (37.5%)

3 (60%)

5 (71.4%)

5 (71.4%)

5 (83.3%)

Diuretic agents

n/a

2 (25%)

5 (100%)

7 (100%)

5 (71.4%)

6 (100%)

Statins

n/a

8 (100%)

2 (40%)

3 (42.9%)

2 (28.6%)

5 (83.3%)

Anticoagulants

n/a

0 (0.0%)

5 (100%)

4 (57.1%)

6 (85.7%)

3 (50.0%)

Sulfonylureas

n/a

3 (37.5%)

0 (0.0%)

1 (14.3%)

0 (0.0%)

2 (33.3%)

DDP-4 inhibitors

n/a

5 (62.5%)

0 (0.0%)

4 (57.1%)

0 (0.0%)

1 (16.7%)

GLP-1 agonists

n/a

2 (25%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

SGLT-2 inhibitors

n/a

2 (25%)

0 (0.0%)

2 (28.6%)

0 (0.0%)

1 (16.7%)

Metformin

n/a

7 (87.5%)

1 (20%)

4 (57.1%)

0 (0.0%)

1 (16.7%)

Insulin

n/a

1 (12.5%)

0 (0.0%)

2 (28.6%)

0 (0.0%)

2 (33.3%)

  1. HC, healthy controls; HFpEF, heart failure with preserved ejection fraction; ADHF, acute decompensated heart failure; T2DM, type-2 diabetes mellitus; NYHA, New York Health Association; LVEF, left ventricular ejection fraction; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DPP-4, dipeptidyl peptidase 4; GLP-1, glucagon-like peptide 1; SGLT2, sodium-glucose co-transporter-2. Continuous variables are shown as mean ± standard error mean and categorical variables as number (%). Anti-platelets included aspirin,clopidogrel, prasugrel, or ticagrelor or a combination of these. *p < 0.05 versus T2DM
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us